Maryam Zia
Hematology · Chicago, ILNPI 1083930101
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. National Marrow Donor Program accounts for 77.2% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,582, more than ten times the $83 reported in 2019. That places this record below the midpoint for hematology clinicians in IL, where the typical reported total is $2,003.
Across 26 payments — averaging $77.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$2K
- Medtronic$88
- Genentech USA, Inc.$61
- Novo Nordisk$58
- Bristol Myers Squibb$44
- Pharmacyclics LLC, An Abbvie Company$43
- plus $163 from 7 others
Across 3 payments — averaging $12,464 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$29K
- Bristol Myers Squibb$8K
What the payments were for
- Speaking & faculty fees$50025%
- Travel & lodging$82441%
- Food & beverage$66333%
- Education$161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 6 | $1,547 |
| Medtronic | 4 | $88 |
| Genentech USA, Inc. | 3 | $61 |
| Novo Nordisk | 3 | $58 |
| Bristol Myers Squibb | 2 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $43 |
| AstraZeneca | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Merck | 1 | $21 |
| Amgen | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Geron Corporation | 1 | $16 |
How this compares
$2,003 in reported general payments places this provider in the 50th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 11 | $153,871 |
| Imatinib Mesylate | 17 | $45,961 |
Paid to pharmacies, not to this prescriber.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Seema SinghalChicago$65K
- Olga FrankfurtChicago$49K
- Deborah KatzChicago$38K
- Martin TallmanChicago$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.